Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

Phase 1 Active not recruiting 20 enrolled ImmunityBio, Inc.

NaSingle-groupOpen-labelTreatment

Summary

Open Label, Phase 1 study of CD19 t-haNK as a single agent and combination with rituximab in subjects with selected CD19+ and CD20+ R/R B-cell non-Hodgkin Lymphoma( NHL).

Timeline

Start: 2024-08-23
Primary completion: 2027-10
Completion: 2027-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD19 t-haNK	Cell therapy	—	—
Subject	Rituximab	Monoclonal antibody	—	—

Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

Summary

Timeline

Drugs

Indications